Registries for orphan drugs: generating evidence or marketing tools?

Independent disease registries for pre-and post-approval of novel treatments for rare diseases are increasingly important for healthcare professionals, patients, regulators and the pharmaceutical industry. Current registries for rare diseases to evaluate orphan drugs are mainly set up and owned by t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hollak, Carla E. M., Sirrs, Sandra, van den Berg, Sibren, van der Wel, Vincent, Langeveld, Mirjam, Dekker, Hanka, Lachmann, Robin, de Visser, Saco J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Position Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469301/
https://www.ncbi.nlm.nih.gov/pubmed/32883346
http://dx.doi.org/10.1186/s13023-020-01519-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469301/
https://www.ncbi.nlm.nih.gov/pubmed/32883346
http://dx.doi.org/10.1186/s13023-020-01519-0

Ejemplares similares